ENDV Endovasc Announces U.S. Patent Office Notification for Resorbable Biodegradable Stent
MONTGOMERY, Texas--(BW HealthWire)--Nov. 15, 2001--Endovasc Ltd. Inc. announced today the U.S. Patent Office (USPTO) has sent the company notification of allowable claims on the company's continuation-in-part of its previous stent patent, U.S. Patent 5,980,551 issued Nov. 9, 1999 for a Totally Resorbable Biodegradable Stent.
``This second patent greatly strengthens our Company's intellectual property built around this technology,'' said the inventor and CEO of Endovasc, Dr. David P. Summers. ``We have three prior stent patents which mention, either in text or in claims, a biodegradable stent with the earliest citation going back to a 1992 filing date.''
The Company's resorbable prosthesis (stent) is a unique concept in the medical device market. There are no stent products currently on the market which will totally degrade by natural biological processes leaving the vessel or organ totally free from any prosthetic remains. The resorbable prosthesis maintains strength needed to acutely open and maintain a vessel, duct, tract or organ confirmation and also precise chronicity controlling the release and delivery of drugs or biologic agents providing a medicinal therapy.
The multi-billion dollar market for medical devices continues to grow, with the top three medical device manufacturers reporting worldwide stent sales during 2000 at over a billion dollars.
About Endovasc Ltd. Inc.
Endovasc Ltd. Inc. is a biopharmaceutical biotech company pioneering drug delivery technology. The Company's products and processes, which include Liprostin(TM) (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, an angiogenic agent), PROSTENT(TM) stent-coating technology, and a biodegradable resorbable prosthesis are covered by patents, license and trade secrets for competing in a multi-billion dollar market.
The foregoing statements are made under the ``Safe Harbor'' Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact:
--------------------------------------------------------------------------------
Contact:
Endovasc Ltd. Inc., Montgomery
New Business Development and Investor Relations:
John (Jack) T. Sorbi, 936/448-2222
Fax: 936/582-2250
jack@endovasc.com
www.endovasc.com |
